Search - tctmd.com

Displaying 501 - 520 of 625

Sort: Relevancy | Date

News Daily News

Dabigatran Carries Higher Risk of Major Bleeds, Lower Risk of Intracranial Hemorrhage

Todd Neale

November 06, 2014

Presentation

Risk of Bleeding With Dabigatran in A-fib

Presenter: I. Hernandez

November 04, 2014

News Daily News

Substantial BP Reductions Appear to Lower Stroke Risk Safely in CAD Patients

Todd Neale

November 02, 2014

News Daily News

Los Descensos Importantes de la Presión Arterial parecen Reducir de Forma Segura el Riesgo de ACV en Pacientes EAC

Todd Neale

November 02, 2014

News Daily News

当将胺碘酮联合华法林使用时，卒中、全身栓塞风险高于阿哌沙班

L.A. McKeown

October 10, 2014

News Daily News

Stroke, Systemic Embolism Risk Higher When Amiodarone Combined with Warfarin Rather Than Apixaban

L.A. McKeown

October 10, 2014

Presentation

Amiodarone, Anticoagulation, and Clinical Events in Patients with A-fib: Insights from ARISTOTLE

Presenter: Greg Flaker

October 07, 2014

News Daily News

CORONOR Registry: Long-term Warfarin Plus Antiplatelet Increases Bleeding in Stable CAD Patients

L.A. McKeown

October 03, 2014

Presentation TCT 2014

Edoxaban in ACS and Atrial Fibrillation: Risk/Benefit Analysis and Future Directions

Presenter: E. Magnus Ohman, Freek W.A. Verheugt, C. Michael Gibson, Michael D. Ezekowitz

September 15, 2014

Presentation TCT 2014

Apixaban in ACS and Atrial Fibrillation: Comparison to Warfarin and Aspirin

Presenter: E. Magnus Ohman, Freek W.A. Verheugt, C. Michael Gibson, Christopher B. Granger

September 15, 2014

Presentation TCT 2014

Rivaroxaban in ACS and Atrial Fibrillation: Randomized Trials, Real-World Data, and Pioneering Efforts

Presenter: E. Magnus Ohman, Freek W.A. Verheugt, C. Michael Gibson

September 15, 2014

Presentation TCT 2014

Dabigatran in ACS and Atrial Fibrillation: MI Risks, Safety in the Elderly, and the RE-DUAL Trial

Presenter: E. Magnus Ohman, Freek W.A. Verheugt, C. Michael Gibson, Laura Mauri

September 15, 2014

News Daily News

High-Dose Edoxaban as Effective as Warfarin for Stroke Prevention in A-fib

Yael L. Maxwell

June 27, 2014

News Daily News

La Dosis Alta de Edoxaban es Igual de Eficaz que la Warfarina en la Prevención de ACV por FA

Yael L. Maxwell

June 27, 2014

Presentation

Cerebrovascular Events in 21,105 Patients with A-fib Randomized to Edoxaban Versus Warfarin

Presenter: Robert P. Giugliano

June 24, 2014

News Daily News

Dialysis Patients with Complex Coronary Disease Fare Better at 5 Years with CABG vs PCI

Caitlin E. Cox

June 24, 2014

Presentation

Importance of Persistent Elevation of Cardiac Biomarkers in A-Fib: RE-LY Substudy

Presenter: Z. Hijazi

May 09, 2014

News Daily News

Persistent Biomarker Elevations in A-fib Patients Foretell Poor Outcomes

Caitlin E. Cox

May 09, 2014

News Daily News

A-fib, Dialysis Dramatically Worsen Outlook for TAVR Patients with Advanced CKD

May 07, 2014

News Daily News

ROCKET AF Substudy: Rivaroxaban Safe, Effective in East Asian Patients

L.A. McKeown

April 29, 2014

Advertisement

Dabigatran Carries Higher Risk of Major Bleeds, Lower Risk of Intracranial Hemorrhage

Risk of Bleeding With Dabigatran in A-fib

Substantial BP Reductions Appear to Lower Stroke Risk Safely in CAD Patients

Los Descensos Importantes de la Presión Arterial parecen Reducir de Forma Segura el Riesgo de ACV en Pacientes EAC

当将胺碘酮联合华法林使用时，卒中、全身栓塞风险高于阿哌沙班

Stroke, Systemic Embolism Risk Higher When Amiodarone Combined with Warfarin Rather Than Apixaban

Amiodarone, Anticoagulation, and Clinical Events in Patients with A-fib: Insights from ARISTOTLE

CORONOR Registry: Long-term Warfarin Plus Antiplatelet Increases Bleeding in Stable CAD Patients

Edoxaban in ACS and Atrial Fibrillation: Risk/Benefit Analysis and Future Directions

Apixaban in ACS and Atrial Fibrillation: Comparison to Warfarin and Aspirin

Rivaroxaban in ACS and Atrial Fibrillation: Randomized Trials, Real-World Data, and Pioneering Efforts

Dabigatran in ACS and Atrial Fibrillation: MI Risks, Safety in the Elderly, and the RE-DUAL Trial

High-Dose Edoxaban as Effective as Warfarin for Stroke Prevention in A-fib

La Dosis Alta de Edoxaban es Igual de Eficaz que la Warfarina en la Prevención de ACV por FA

Cerebrovascular Events in 21,105 Patients with A-fib Randomized to Edoxaban Versus Warfarin

Dialysis Patients with Complex Coronary Disease Fare Better at 5 Years with CABG vs PCI

Importance of Persistent Elevation of Cardiac Biomarkers in A-Fib: RE-LY Substudy

Persistent Biomarker Elevations in A-fib Patients Foretell Poor Outcomes

A-fib, Dialysis Dramatically Worsen Outlook for TAVR Patients with Advanced CKD

ROCKET AF Substudy: Rivaroxaban Safe, Effective in East Asian Patients

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content